Cargando…

Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy

BACKGROUND: The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small cell lung cancer (SCLC) patients who received first‐line platinum‐containing chemotherapy. METHODS: A total of 234 SCLC patients, who received first‐line platinum‐bas...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Man, Chi, Xiaorui, Shi, Xinyan, Sun, Yang, Yang, Xue, Wang, Leirong, Wang, Bingrui, Li, Hongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636211/
https://www.ncbi.nlm.nih.gov/pubmed/34725930
http://dx.doi.org/10.1111/1759-7714.13581
_version_ 1784608488847048704
author He, Man
Chi, Xiaorui
Shi, Xinyan
Sun, Yang
Yang, Xue
Wang, Leirong
Wang, Bingrui
Li, Hongmei
author_facet He, Man
Chi, Xiaorui
Shi, Xinyan
Sun, Yang
Yang, Xue
Wang, Leirong
Wang, Bingrui
Li, Hongmei
author_sort He, Man
collection PubMed
description BACKGROUND: The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small cell lung cancer (SCLC) patients who received first‐line platinum‐containing chemotherapy. METHODS: A total of 234 SCLC patients, who received first‐line platinum‐based chemotherapy between 2013 and 2018, were retrospectively analyzed. The data of hematological characteristics, age, gender, ECOG score, staging, metastatic site, smoking history, chemotherapy cycle, thoracic radiotherapy and hyponatremia were collected. Overall survival was calculated using the Kaplan‐Meier method. The statistically significant factors in the univariate analysis were selected for the multivariate COX model analysis. RESULTS: Age, ECOG score, stage, thoracic radiotherapy, hyponatremia, liver metastasis, brain metastasis, bone metastasis, LDH, NSE and neutrophil‐to‐lymphocyte ratio (NLR) were closely correlated to OS in the univariate analysis. Furthermore, the multivariate analysis revealed that age (<65 years), ECOG score (<2 points), limited‐stage (LD), thoracic radiotherapy and LDH <215.70 U/L were the independent prognostic factors for survival. The median OS time was worse for patients with LDH ≥215.70 U/L. In the subgroup analysis, LDH ≥215.70 U/L was significant for survival in both limited and extensive disease. Patients who achieved CR + PR in the first‐line treatment had lower initial LDH levels. It was found that the pretreatment LDH increased the incidence of patients with liver metastasis. CONCLUSIONS: Positive independent prognostic factors for SCLC patients were age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L. These factors may be useful for stratifying patients with SCLC for treatment approaches. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L are the positive independent prognostic factors for SCLC patients. WHAT THIS STUDY ADDS: The current study provided more references for SCLC diagnosis and treatment and determined more factors for stratifying patients with SCLC for treatment approaches.
format Online
Article
Text
id pubmed-8636211
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-86362112021-12-08 Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy He, Man Chi, Xiaorui Shi, Xinyan Sun, Yang Yang, Xue Wang, Leirong Wang, Bingrui Li, Hongmei Thorac Cancer Original Articles BACKGROUND: The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small cell lung cancer (SCLC) patients who received first‐line platinum‐containing chemotherapy. METHODS: A total of 234 SCLC patients, who received first‐line platinum‐based chemotherapy between 2013 and 2018, were retrospectively analyzed. The data of hematological characteristics, age, gender, ECOG score, staging, metastatic site, smoking history, chemotherapy cycle, thoracic radiotherapy and hyponatremia were collected. Overall survival was calculated using the Kaplan‐Meier method. The statistically significant factors in the univariate analysis were selected for the multivariate COX model analysis. RESULTS: Age, ECOG score, stage, thoracic radiotherapy, hyponatremia, liver metastasis, brain metastasis, bone metastasis, LDH, NSE and neutrophil‐to‐lymphocyte ratio (NLR) were closely correlated to OS in the univariate analysis. Furthermore, the multivariate analysis revealed that age (<65 years), ECOG score (<2 points), limited‐stage (LD), thoracic radiotherapy and LDH <215.70 U/L were the independent prognostic factors for survival. The median OS time was worse for patients with LDH ≥215.70 U/L. In the subgroup analysis, LDH ≥215.70 U/L was significant for survival in both limited and extensive disease. Patients who achieved CR + PR in the first‐line treatment had lower initial LDH levels. It was found that the pretreatment LDH increased the incidence of patients with liver metastasis. CONCLUSIONS: Positive independent prognostic factors for SCLC patients were age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L. These factors may be useful for stratifying patients with SCLC for treatment approaches. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L are the positive independent prognostic factors for SCLC patients. WHAT THIS STUDY ADDS: The current study provided more references for SCLC diagnosis and treatment and determined more factors for stratifying patients with SCLC for treatment approaches. John Wiley & Sons Australia, Ltd 2021-11-01 2021-12 /pmc/articles/PMC8636211/ /pubmed/34725930 http://dx.doi.org/10.1111/1759-7714.13581 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
He, Man
Chi, Xiaorui
Shi, Xinyan
Sun, Yang
Yang, Xue
Wang, Leirong
Wang, Bingrui
Li, Hongmei
Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_full Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_fullStr Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_full_unstemmed Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_short Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_sort value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636211/
https://www.ncbi.nlm.nih.gov/pubmed/34725930
http://dx.doi.org/10.1111/1759-7714.13581
work_keys_str_mv AT heman valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT chixiaorui valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT shixinyan valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT sunyang valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT yangxue valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT wangleirong valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT wangbingrui valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT lihongmei valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy